1
|
Shen R, Ge Y, Qin Y, Gao H, Yu H, Wu H, Song H. Sporoderm-broken spores of Ganoderma lucidum modulate hepatoblastoma malignancy by regulating RACK1-mediated autophagy and tumour immunity. J Cell Mol Med 2024; 28:e18223. [PMID: 38451046 PMCID: PMC10919157 DOI: 10.1111/jcmm.18223] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/03/2023] [Revised: 02/15/2024] [Accepted: 02/23/2024] [Indexed: 03/08/2024] Open
Abstract
Hepatoblastoma (HB), a primary liver tumour, is notorious for its high metastatic potential and poor prognosis. Ganoderma lucidum, an edible mushroom species utilized in traditional Chinese medicine for addressing various tumour types, presents an intriguing avenue for HB treatment. However, the effectiveness of G. lucidum in managing HB and its underlying molecular mechanism necessitates further exploration. Standard in vitro assays were conducted to evaluate the impact of sporoderm-broken spores of G. lucidum (SBSGL) on the malignant characteristics of HB cells. The mechanism of SBSGL in treating HB and its tumour immunomodulatory effects were explored and validated by various experiments, including immunoprecipitation, Western blotting, mRFP-GFP-LC3 adenovirus transfection and co-localization analysis, as well as verified with in vivo experiments in this regard. The results showed that SBSGL effectively inhibited the malignant traits of HB cells and suppressed the O-GlcNAcylation of RACK1, thereby reducing its expression. In addition, SBSGL inhibited immune checkpoints and regulated cytokines. In conclusion, SBSGL had immunomodulatory effects and regulated the malignancy and autophagy of HB by regulating the O-GlcNAcylation of RACK1. These findings suggest that SBSGL holds promise as a potential anticancer drug for HB treatment.
Collapse
Affiliation(s)
- Rui Shen
- Graduate SchoolAnhui University of Chinese MedicineHefeiChina
| | - Yang Ge
- Graduate SchoolAnhui University of Chinese MedicineHefeiChina
| | - Yunpeng Qin
- Graduate SchoolAnhui University of Chinese MedicineHefeiChina
| | - Hang Gao
- Graduate SchoolAnhui University of Chinese MedicineHefeiChina
| | - Hongyan Yu
- School of Integrated Chinese and Western MedicineAnhui University of Chinese MedicineHefeiChina
| | - Huazhang Wu
- Anhui Province Key Laboratory of Translational Cancer ResearchBengbu Medical CollegeBengbuChina
| | - Hang Song
- School of Integrated Chinese and Western MedicineAnhui University of Chinese MedicineHefeiChina
- Anhui Province Key Laboratory of Translational Cancer ResearchBengbu Medical CollegeBengbuChina
| |
Collapse
|
2
|
Zhao X, Lin G, Liu T, Zhang X, Xu Y. Comparative Analysis of Metabolic Compositions and Trace Elements of Ornithogalum caudatum with Different Growth Years. ACS Omega 2023; 8:23889-23900. [PMID: 37426248 PMCID: PMC10324082 DOI: 10.1021/acsomega.3c02310] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 04/06/2023] [Accepted: 06/08/2023] [Indexed: 07/11/2023]
Abstract
As a traditional medicine with extensive history, Ornithogalum caudatum has high nutritional and medicinal value. However, its quality evaluation criteria are insufficient because it is not included in the pharmacopeia. Simultaneously, it is a perennial plant, and the medicinal ingredients change with the growth years. Currently, studies on the synthesis and accumulation of metabolites and elements in O. caudatum during different growth years are unavailable. To address this issue, in this study, the 8 main active substances, metabolism profiles, and 12 trace elements of O. caudatum from different growth years (1, 3, and 5 years old) were analyzed. The main substances of O. caudatum changed significantly in different years of growth. Saponin and sterol contents increased with age; however, the polysaccharide content decreased. For metabolism profiling, ultrahigh-performance liquid chromatography tandem mass spectrometry was performed. Among the three groups, 156 differential metabolites with variable importance in projection values >1.0 and p < 0.05 were identified. Among the differential metabolites, 16 increased with increasing years of growth and have the potential to become age-identified markers. A trace element study showed that the contents of K, Ca, and Mg were higher, and the ratio of Zn/Cu was less than 0.1%. Heavy metal ions in O. caudatum did not increase with age. The results of this study provide a basis to evaluate the edible values of O. caudatum and facilitate further exploitation.
Collapse
Affiliation(s)
- Xueliang Zhao
- Key
Laboratory for Metabolic Regulation and Activity Research of Medicinal
Plants, Baicheng Medical College, Baicheng, Jilin 137000, China
- College
of Life Sciences, Baicheng Normal University, Baicheng, Jilin 137000, China
| | - Guangyu Lin
- Animal
Husbandry Information Center, Changchun, Jilin 130000, China
- Jilin
Agricultural University, Changchun, Jilin 130018, China
| | - Tong Liu
- Key
Laboratory for Metabolic Regulation and Activity Research of Medicinal
Plants, Baicheng Medical College, Baicheng, Jilin 137000, China
- College
of Life Sciences, Baicheng Normal University, Baicheng, Jilin 137000, China
| | - Xue Zhang
- Key
Laboratory for Metabolic Regulation and Activity Research of Medicinal
Plants, Baicheng Medical College, Baicheng, Jilin 137000, China
- College
of Life Sciences, Baicheng Normal University, Baicheng, Jilin 137000, China
| | - Yang Xu
- Key
Laboratory for Metabolic Regulation and Activity Research of Medicinal
Plants, Baicheng Medical College, Baicheng, Jilin 137000, China
- College
of Life Sciences, Baicheng Normal University, Baicheng, Jilin 137000, China
| |
Collapse
|
3
|
Pu Q, Yu L, Wang X, Yan H, Xie Y, Jiang Y, Yang Z. Immunomodulatory Effect of Traditional Chinese Medicine Combined with Systemic Therapy on Patients with Liver Cancer: A Systemic Review and Network Meta-analysis. J Cancer 2022; 13:3280-3296. [PMID: 36118529 PMCID: PMC9475362 DOI: 10.7150/jca.74829] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/07/2022] [Accepted: 08/20/2022] [Indexed: 11/17/2022] Open
Abstract
Objective: As immune combination therapy in the treatment of liver cancer made significant achievements, and the modulating effect of traditional Chinese medicine (TCM) on immunity gradually appeared. The main purpose of this study was to study the effect of different TCM combined with systemic therapy (ST) on immune regulation in patients with liver cancer, as well as the efficacy and safety of combined therapy, and to find the best combined application scheme by ranking. Methods: Nine electronic databases were searched from January 1, 2010, to November 12, 2021, to search for RCTs of TCM combined ST in the field of liver cancer for literature screening, quality evaluation and data extraction. STATA 15.0 and RevMan 5.3 software were used to conduct network meta-analysis to analyze and explore the significance of TCM combined ST in immune regulation, efficacy and safety in clinical application. The probability value of the surface under the cumulative ranking curve was used to rank the processing studied. Results: A total of 25 studies involving 2,152 participants were included in the network meta-analysis, including six traditional Chinese medicine injections and seven proprietary Chinese medicines. The results showed that Dahuang Zhechong Wan and Kangai injection combined with ST were the best choices for immune regulation. Moreover, the Huaier granule was the best choice to reduce vascular endothelial growth factors. Conclusion: For patients with liver cancer, TCM combined with ST was better than that of ST alone and can significantly improve the immune function of patients as well as the efficacy and safety of treatment. However, given the limited sample size and methodological quality of the trials that we included in our study, more centralized and randomized controlled trials with a large sample size are required to verify our findings.
Collapse
Affiliation(s)
- Qing Pu
- Center of Integrative Medicine, Beijing Ditan Hospital, Capital Medical University, Beijing, China
| | - Lihua Yu
- Center of Integrative Medicine, Beijing Ditan Hospital, Capital Medical University, Beijing, China
| | - Xinhui Wang
- Center of Integrative Medicine, Beijing Ditan Hospital, Capital Medical University, Beijing, China
| | - Huiwen Yan
- Center of Integrative Medicine, Beijing Ditan Hospital, Capital Medical University, Beijing, China
| | - Yuqing Xie
- Center of Integrative Medicine, Beijing Ditan Hospital, Capital Medical University, Beijing, China
| | - Yuyong Jiang
- Center of Integrative Medicine, Beijing Ditan Hospital, Capital Medical University, Beijing, China
| | - Zhiyun Yang
- Center of Integrative Medicine, Beijing Ditan Hospital, Capital Medical University, Beijing, China
| |
Collapse
|
4
|
Song N, Cui K, Zhang K, Yang J, Liu J, Miao Z, Zhao F, Meng H, Chen L, Chen C, Li Y, Shao M, Zhang J, Wang H. The Role of m6A RNA Methylation in Cancer: Implication for Nature Products Anti-Cancer Research. Front Pharmacol 2022; 13:933332. [PMID: 35784761 PMCID: PMC9243580 DOI: 10.3389/fphar.2022.933332] [Citation(s) in RCA: 15] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/30/2022] [Accepted: 05/27/2022] [Indexed: 12/20/2022] Open
Abstract
N6-methyladenosine (m6A) RNA methylation is identified as the most common, abundant and reversible RNA epigenetic modification in messenger RNA (mRNA) and non-coding RNA, especially within eukaryotic messenger RNAs (mRNAs), which post-transcriptionally directs many important processes of RNA. It has also been demonstrated that m6A modification plays a pivotal role in the occurrence and development of tumors by regulating RNA splicing, localization, translation, stabilization and decay. Growing number of studies have indicated that natural products have outstanding anti-cancer effects of their unique advantages of high efficiency and minimal side effects. However, at present, there are very few research articles to study and explore the relationship between natural products and m6A RNA modification in tumorigenesis. m6A is dynamically deposited, removed, and recognized by m6A methyltransferases (METTL3/14, METTL16, WTAP, RBM15/15B, VIRMA, CBLL1, and ZC3H13, called as “writers”), demethylases (FTO and ALKBH5, called as “erasers”), and m6A-specific binding proteins (YTHDF1/2/3, YTHDC1/2, IGH2BP1/2/3, hnRNPs, eIF3, and FMR1, called as “readers”), respectively. In this review, we summarize the biological function of m6A modification, the role of m6A and the related signaling pathway in cancer, such as AKT, NF-kB, MAPK, ERK, Wnt/β-catenin, STAT, p53, Notch signaling pathway, and so on. Furthermore, we reviewed the current research on nature products in anti-tumor, and further to get a better understanding of the anti-tumor mechanism, thus provide an implication for nature products with anti-cancer research by regulating m6A modification in the future.
Collapse
Affiliation(s)
- Na Song
- Department of Pathology, Key Laboratory of Clinical Molecular Pathology, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, China
- Department of Pathology, Xinxiang Medical University, Xinxiang, China
| | - Kai Cui
- Department of Pathology, Xinxiang Medical University, Xinxiang, China
| | - Ke Zhang
- Department of Pathology, Xinxiang Medical University, Xinxiang, China
| | - Jie Yang
- Department of Pathology, Xinxiang Medical University, Xinxiang, China
| | - Jia Liu
- Department of Pathology, Xinxiang Medical University, Xinxiang, China
| | - Zhuang Miao
- Department of Pathology, Xinxiang Medical University, Xinxiang, China
| | - Feiyue Zhao
- Department of Pathology, Xinxiang Medical University, Xinxiang, China
| | - Hongjing Meng
- Department of Pathology, Xinxiang Medical University, Xinxiang, China
| | - Lu Chen
- Department of Pathology, Xinxiang Medical University, Xinxiang, China
| | - Chong Chen
- Department of Pathology, Xinxiang Medical University, Xinxiang, China
| | - Yushan Li
- School of Public Health, Xinxiang Medical University, Xinxiang, China
| | - Minglong Shao
- The Second Affiliated Hospital of Xinxiang Medical University, Xinxiang, China
| | - Jinghang Zhang
- Department of Pathology, Key Laboratory of Clinical Molecular Pathology, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, China
- *Correspondence: Jinghang Zhang, ; Haijun Wang,
| | - Haijun Wang
- Department of Pathology, Key Laboratory of Clinical Molecular Pathology, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, China
- Department of Pathology, Xinxiang Medical University, Xinxiang, China
- *Correspondence: Jinghang Zhang, ; Haijun Wang,
| |
Collapse
|